
0000081316

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name		
Novartis		
2. Address Check if different than previously reported		
701 Pennsylvania Ave. NW	Suite 725	
Washington D	C 20004	USA
3. Principal place of business (if different than line 2)		
City State/Zi	p or Country	
4a. Contact Name b. Telephone number	c. E-mail 5. Senate ID	#
Mrs. Andrea McCabe 202-638-7429 andr	ea.mccabe@novartis.com	9204-12
7. Client Name 💌 Self Novartis	6. House ID 3	# 3589000
9. Check if this filing amends a previously filed version of this report  10. Check if this is a Termination Report   □  □ Termination Date  INCOME OF EXPENSES. Complete Fither Line 1		ying Activit
INCOME OR EXPENSES - Complete Either Line 1  12. Lobbying Firms	2 OK Line 13  13. Organizations	,,,,,,
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this were:	s reporting p
Less than \$10,000	Less than \$10,000	
\$10,000 or more	\$10,000 or more <b>∑</b> ⇒ \$ 1,927	7,017
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	14. REPORTING METHOD. Check box to indi accounting method. See instructions for description  Method A. Reporting amounts using LDA de	on of option
activities on behalf of the client).	Method B. Reporting amounts under section 6033(b)(8) of Internal Revenue Code	
	Method C. Reporting amounts under section Revenue Code	162(e) of the
		Edit >
Signature Andrea L McCabe Discourse (2003.22,15 14-07 03 -80007	Date <u>2/13/2006</u>	i
Printed Name and Title	Federal Government Relations	

	sue area code	(one per page)
H.R. 2218 S.930 food H.R. 2090	d and Drug Administration s Food and Drug Administra Fair Access to clinical Tria	ation Improvement Act of 2005
Senate	of Congress and Federal a	gencies contacted Check if None
18. Name of 6	each individual who acted	as a lobbyist in this issue area  Covered Official Position (if applicable)
James	Elkin	Vice President, Federal Government Relations
Daniel	Casserly	Executive Director, Federal Government Relation
Thomas	Giles	Executive Director, Federal Government Relation
Deborah	Bumbaugh	Director, Federal Government Relations
David	Drake	Executive Director, Federal Government Relation
Sarah	Haller	Executive Director, International and Public Affa
Novartis AG I		e specific issues listed on line 16 above Check if None clicies, either laws or regulations, commercially benefit Novartis Cofit.
<b>-</b> -	Pocument digitally signed o	on Page 1. Date 2/13/2006
Signature		

Client Name \_\_\_Novartis

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**,

Registrant Name \_ Novartis

information as requested. Attach additional page(s) as needed.

Ö

4.
M
him
¢¢
C

Novartis	Novartis
Registrant Name	Client Name

## ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

H.R. 3428 OTC Medicine Tax Fairness Act of 2005 S.1514 OTC Medicine Tax Fairness Act of 2005

S.172 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contact lenses a medical devices, and for other purposes.

H.R. 371 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contact lense medical devices, and for other purposes.

S.103 Combat Meth Act of 2005 H.R. 314 Combat Meth Act of 2005

S.950 Elimination of Neglected Diseases Act of 2005

H.R. 3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006

H.R. 2744 Agriculture, Rural Development, Food and Drug Admin. and Related Agenices Appropriations Act, 2006

Federal Food, Drug and Cosmetic Act (Section 767)

S. Res. 302 Reconcilliation Bill

H.R. 2051 Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act of 2005 S. 173 Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act of 2005

Drug Importation
Medicare Part B and Part D
Sickle Cell Anemia
Immunosuppressant Legislation
Cancer Therapies Legislation
Gene Therapy
Direct to Consumer Advertising
Medicare Prescription Drugs and Modernization Act

Ö

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)			
16. Specific lobbying issues			
	rld Trade Organization le Agreements		
1	of Congress and Federal ager by for International Development (		
18. Name of	each individual who acted as Name	a lobbyist in this issue area  Covered Official Position (if applicable)	
Sarah	Haller	Executive Director, International and Public Affa	
Novartis AG t		ecific issues listed on line 16 above Check if None es, either laws or regulations, commercially benefit Novartis Cor	
	,		

Client Name \_\_\_Novartis

Registrant Name \_\_\_\_Novartis